Compare iShares Gold Trust (IAU) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs Novartis AG — how do they compare? iShares Gold Trust trades at $78.87 (market cap $61.51B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 4.4× iShares Gold Trust's market cap, and Novartis AG pays a 3.31% dividend while iShares Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 49 Days and Novartis AG for 82 Days on average.
| IAU | NVS | |
|---|---|---|
Market Cap | $61.51B | $268.57B |
Volume | 3,206,729 | 1,532,573 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $168.62 |
52-Week Low | $74.21 | $121.80 |
Typical Hold Time | 49 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU stock trades at $77.66 with a modest 0.78% daily gain amid bearish technical signals. The stock faces significant selling pressure with moving averages indicating a strong downtrend while oscillators remain neutral. Recent news highlights gold's sensitivity to interest rate expectations and Treasury yield movements, with mixed sentiment from financial media regarding near-term prospects.
The outlook remains cautious with technical indicators favoring sellers, though oversold conditions could present tactical opportunities. Key risks include persistent rate hike expectations and dollar strength, while institutional positioning suggests defensive sentiment prevails in the current macroeconomic environment.
Novartis (NVS) trades at $143.11, down 0.12% with a bearish technical signal. The stock shows strong fundamentals with 24.67% net margin and $14B net income, though recent earnings were mixed with a Q1 miss. Analyst consensus is cautious with 68% hold ratings and a $146 target. Recent $7.8B licensing deal with China's Abogen highlights strategic moves amid pipeline setbacks.
Outlook remains balanced: valuation metrics appear reasonable (P/E 21.6) and profitability is robust, but clinical trial failures and investor scrutiny over M&A strategy pose risks. The stock trades near consensus target with institutional sentiment leaning neutral amid ongoing pipeline execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
